鋭明技術(002970.SZ):高管陳建華親屬短線交易
格隆匯 2 月 9日丨鋭明技術(002970.SZ)公佈,公司於今日收到公司副總經理陳建華出具的《關於本人親屬買賣公司股票的情況説明》,陳建華配偶陳梅香於2021年1月29日至2021年2月2日期間買賣公司股票,其買賣行為構成了短線交易。
經核查,陳建華及陳梅香個人證券賬户關於交易公司股票的具體情況如下:陳梅香於2021年1月29日通過集中競價買入900股、2021年2月2日通過集中競價賣出900股;陳建華於2021年2月2日通過集中競價買入2000股。
按照規定,陳梅香此次所得收益作為此次短線交易的獲利金額3042元已全額上繳公司。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.